Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-PEG 20 in Acute Myeloid Leukemia
NCT01910012Phase 2Completed
- Sponsor
- Polaris Group
- Start
- Jan 2015
- Primary completion
- Sep 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of Pegargiminase in acute myeloid leukemia (AML), sponsored by Polaris Group. Started Jan 2015; status: completed.
02
Drugs
Pegargiminase
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01910012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01910012.